Tranexamic acid, Remifentanil, and Hydralazine and the bleeding volume

Comparison of Tranexamic acid, Remifentanil, and Hydralazine on the bleeding volume during Dacryocystorhinostomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210614051574N10

Enrollment

Registered

2022-04-11

Start date

2019-07-21

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dacryocystitis. Unspecified dacryocystitis

Interventions

Intervention 1: Intervention group 1: Candidate patients for dacryocystorhinostomy surgery In this group, ten minutes before the start of surgery, remifentanil made by Abu Reihan company is injected a

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age between 20 and 80 years Being a candidate for Dacryocystorhinostomy Having a score of 1 or 2 based on the American Society of Anesthesiologists Signing the written informed consent to participate in this study

Exclusion criteria

Exclusion criteria: Uncontrolled systemic disease History of malignant hyperthermia Refusing to continue participating in the study Incidence of any complication during surgery

Design outcomes

Primary

Measure	Time frame
Bleeding. Timepoint: End of surgery. Method of measurement: Measuring the blood collected in the suction bottle at the end of surgery.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDarioush Moradi Farsani

Esfahan University of Medical Sciences

mohammadsharifi.ghasem@gmail.com+98 31 3729 4005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026